本報道最初發表于Endpoints News。請點擊這里查看原文
With its fourth biotech acquisition of the year, Eli Lilly is further bolstering its gene therapy portfolio as other large drugmakers reassess their work in the complex, commercially-strained field.
今年第四次收購生物科技公司之際，禮來(Eli Lilly)正進一步充實其基因療法版圖，而其他大型制藥商則在重新評估這一復雜且商業壓力巨大的領域內的布局。
您已閱讀7%（306字），剩余93%（3908字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。